Combination with vorinostat overcomes ABT-263 (navitoclax) resistance of small cell lung cancer

Area of Science:

• Oncology
• Molecular Biology
• Cancer Therapeutics

Background:

• Small cell lung cancer (SCLC) is aggressive with high mortality.
• Resistance to apoptosis is a key challenge in SCLC treatment.
• BH3 mimetics (e.g., ABT-263) target pro-survival BCL-2 proteins but SCLC sensitivity varies.

Purpose of the Study:

• To investigate the efficacy of combining ABT-263 with HDAC inhibitors in SCLC.
• To explore the molecular mechanisms underlying apoptosis induction by this combination therapy.

Main Methods:

• Treatment of various SCLC cell lines with ABT-263 and vorinostat (an HDAC inhibitor).
• Assessment of apoptosis induction and its dependence on specific BCL-2 family proteins (Noxa, BIM).
• Analysis of BCL-XL and MCL-1 regulation and BAK release.

Main Results:

• The combination of ABT-263 and vorinostat effectively induced apoptosis in diverse SCLC cell lines, including resistant ones.
• Apoptosis was mediated by Noxa and/or BIM in some cell lines.
• Other cell lines showed apoptosis via BCL-XL downregulation and BAK release from BCL-XL and MCL-1.

Conclusions:

• Combining HDAC inhibitors with BCL-2 inhibitors represents a viable and effective therapeutic strategy for SCLC.
• This combination overcomes resistance mechanisms and induces apoptosis through multiple pathways.
• Further investigation into this combination regimen is warranted for SCLC treatment.